CLA1 Stock Chart & Stats
€0.58
€0.04(3.20%)
At close: 4:00 PM EST
€0.58
€0.04(3.20%)
Day’s Range― - ―
52-Week Range€0.06 - €36.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€9.32M
Enterprise Value€5.55
Total Cash (Recent Filing)€2.77M
Total Debt (Recent Filing)€732.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1448.00
Shares Outstanding1,144,588
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€23.60Price Target Upside3969.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Debt ProfileAkari's very low reported debt reduces immediate refinancing and interest-rate risks, preserving operational flexibility. For a pre-commercial biotech reliant on R&D, low leverage lengthens runway options and reduces bankruptcy risk while management pursues strategic funding or partnerships.
Strategic Research Collaboration With WhitehawkThe structured preclinical collaboration to test Akari's PH1 payload with Whitehawk's ADC platform is a material pipeline development. It can generate de-risking data, broaden clinical options, and create partnership/M&A pathways—an enduring structural boost to technology validation and program optionality.
Shareholder-approved Capital FlexibilityAGM approvals that authorize share issuances, new warrants and broad allotment powers provide durable financing flexibility. This corporate governance support allows management to pursue equity or warrant financings and structured placements to fund R&D without repeated shareholder reauthorization.
Bears Say
Zero Revenue / Pre-commercial ProfileSustained lack of revenue means the company remains fully dependent on external funding and R&D progress. Without commercial products, operational viability hinges on clinical success or partnership deals, which creates structural funding and execution risks over the medium term.
Sustained Negative Operating And Free Cash FlowPersistent negative operating and free cash flow necessitate recurring capital raises or partnerships. Ongoing cash burn constrains strategic flexibility, risks dilution from frequent financings, and forces management to prioritize near-term liquidity over long-term program investments.
Eroding Equity Base And Widening LossesMaterial decline in equity alongside sustained net losses signals structural value erosion and potential dilution. A weakened equity cushion reduces financial resilience to shocks, limits borrowing capacity, and can amplify governance and investor-confidence challenges over multiple quarters.
Akari Therapeutics News
CLA1 FAQ
What was Akari Therapeutics PLC (ADR)’s price range in the past 12 months?
Akari Therapeutics PLC (ADR) lowest stock price was €0.06 and its highest was €36.00 in the past 12 months.
What is Akari Therapeutics PLC (ADR)’s market cap?
Akari Therapeutics PLC (ADR)’s market cap is €9.32M.
When is Akari Therapeutics PLC (ADR)’s upcoming earnings report date?
Akari Therapeutics PLC (ADR)’s upcoming earnings report date is May 20, 2027 which is in 301 days.
How were Akari Therapeutics PLC (ADR)’s earnings last quarter?
Currently, no data Available
Is Akari Therapeutics PLC (ADR) overvalued?
According to Wall Street analysts Akari Therapeutics PLC (ADR)’s price is currently Undervalued.
Does Akari Therapeutics PLC (ADR) pay dividends?
Akari Therapeutics PLC (ADR) does not currently pay dividends.
What is Akari Therapeutics PLC (ADR)’s EPS estimate?
Akari Therapeutics PLC (ADR)’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics PLC (ADR) have?
Akari Therapeutics PLC (ADR) has 1,144,588 shares outstanding.
What happened to Akari Therapeutics PLC (ADR)’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Akari Therapeutics PLC (ADR)?
Currently, no hedge funds are holding shares in DE:CLA1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics PLC (ADR)
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
CLA1 Stock 12 Month Forecast
Average Price Target
€23.60
▲(3969.11% Upside)